Publication | Closed Access

Four years of tenofovir monotherapy for NUC naïve field practice European patients suppresses HBV replication in most patients with a favorable renal safety profile but does not prevent HCC in patients with or without cirrhosis

Hbv ReplicationHepatologyViral HepatitisAntiviral TherapyHepatitisVirologyTenofovir MonotherapyChronic Viral InfectionAntiviral DrugMedicineMost Patients